

## REMARKS

Claims 1-17 and 19 are in this application. Claims 18, 20 and 21 have been cancelled.

Claims 1-9 and 16 have been amended to insert a period at the end of the claim.

Claims 1 - 9 have been amended to insert compound in place of pyrrolobenzodiazepine hybrid. Claim 10 has been amended to insert the structure in place of the phrase pyrrolobenzodiazepine hybrid at the end of the claim.

Claim 17 was amended to define the subject as a mammal.

These amendments are being made to put the claims in better form for allowance. It is submitted that Claims 1-17 comply with the requirements of 35 USC 112, second paragraph.

In view of the cancellation of Claim 21, the Examiner's statement that this claim does not comply with 35 USC 101 is moot.


According to the Official Action, Claims 17-19 are rejected under 35 USC 112, first paragraph as failing to comply with the enablement requirement on the basis that the specification does not provide enablement for the treatment of cancer generally. This rejection is respectfully traversed.

Claim 17 has been amended to include the subject matter of Claim 20.

Therefore, it is respectfully requested that this rejection be withdrawn.

It is submitted that the application is in condition for allowance and favorable consideration is respectfully requested.

Respectfully submitted,



---

JANET I. CORD  
LADAS & PARRY  
26 WEST 61<sup>ST</sup> STREET  
NEW YORK, NEW YORK 10023  
REG.NO.33,778(212)708-1935